Skip to contentP
Processa Pharmaceuticals, Inc.
P
PCSAProcessa Pharmaceuticals, Inc. Q3 2018 · 10-Q
Revenue—
Net Income-$852.82K-$852.82KN/M vs Q3 2017 EPS Diluted-$0.02-$0.02N/M vs Q3 2017 Operating Income-$1,062,971N/M Operating Cash Flowderived-$1,010,752N/M
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Processa Pharmaceuticals, Inc. · CIK 1533743 · Engraved from SEC EDGAR
ended Sep 30, 2018 · filed Nov 14, 2018 · 45 d after period end